-
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-03-11 Huang Xinrui, Xu Min, Cao Min, Xu Chenyi
To develop and internally validate a prediction model for identifying patients with hematologic diseases of fall risk.This is a prospective cohort study from a prospective collection of data for 6 ...
-
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-03-05 Ying Luo, Chen Li, Yuanchen Niu, Shuanzhi Wu, Jingyuan Tian, Zhiqin Hu, Jin He, Zhixin Zhang, Haiyan Liu, Yongmei Li, Tenghua Wang, Yi Fang
To evaluate the efficacy and safety of pomalidomide in combination treatment of relapsed/refractory multiple myeloma (RRMM).Published clinical trials were searched in the Cochrane Library, PubMed, ...
-
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-02-20 Inés Gómez Seguí, María Eva Mingot Castellano, Cristina Pascual Izquierdo, Javier de la Rubia
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening disorder. Caplacizumab has been the latest drug incorporated into the initial treatment of acute episodes, allowing ...
-
Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-02-19 Drew Provan, Jecko Thachil, María Teresa Álvarez Román
Immune thrombocytopenia (ITP), a disease that commonly presents with an increased risk of bleeding, can also paradoxically produce an increased risk of thromboembolic events. The risk of thromboemb...
-
The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-02-12 Yang Liu, Bo Li, Xiaomin Chen, Hao Xiong, Chunlan Huang
Immunomodulatory drugs (IMiDs) are widely used in the management of newly diagnosed and relapsed/refractory multiple myeloma patients. These agents show their potential effect on myeloma bone disea...
-
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-02-07 Raul Cordoba, Joaquín Sánchez-García, Eva Domingo-Domenech, Javier López Jiménez, Antonio Martínez Pozo, Cecilia Carpio, Ángeles Bendaña, Ana Julia González, Sonia González de Villambrosia, José Gómez Codina, Belén Navarro, Guillermo Rodríguez, Andrea Naves, Lourdes Baeza, Alejandro Martín García-Sancho
An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). 18F-fluorodeoxyglucose (18F-FDG) positron e...
-
Overexpression of SCN5A overcomes ABC transporter-mediated multidrug resistance in acute myeloid leukemia through promoting apoptosis Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-02-02 Kun Xu, Xian-Xu Zhuang, Xiao-Wei Shi
This study aimed to explore the effect and mechanism of SCN5A overcoming ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR) in acute myeloid leukemia (AML) through promoting...
-
Do we need more guidance on thrombophilia testing? Challenges and special considerations Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-01-22 Francesco Marongiu, Maria Filomena Ruberto, Silvia Marongiu, Antonella Mameli, Doris Barcellona
Thrombophilia testing (TT) is a laboratory procedure designed to detect the risk factors involved in the pathogenesis of vascular occlusions. The role of TT is also controversial because it has a l...
-
Graft-versus-host disease after an outpatient peripheral blood hematopoietic cell transplant using reduced-intensity conditioning: a single-center LATAM experience Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-01-17 José Carlos Jaime-Pérez, Jesús Daniel Meléndez-Flores, Jorge Valdespino-Valdes, Andrés Gómez-De León, Perla Rocío Colunga-Pedraza, César Homero Gutiérrez-Aguirre, Olga Graciela Cantú-Rodríguez, David Gómez-Almaguer
HLA compatibility predicts allogeneic hematopoietic cell transplant (allo-HCT) and graft-versus-host disease (GvHD) outcomes. There is insufficient information regarding GvHD outcomes for outpatien...
-
Correction Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-01-10
Published in Expert Review of Hematology (Vol. 17, No. 1-3, 2024)
-
Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis Expert Rev. Hematol. (IF 2.8) Pub Date : 2024-01-04 Yixin Zhai, Ju Hong, Jinhuan Wang, Yanan Jiang, Wenqi Wu, Yangyang Lv, Jing Guo, Linyan Tian, Huimeng Sun, Yuhang Li, Cheng Li, Hongjie Zhan, Zhigang Zhao
This study evaluated the benefits and risks of patients with refractory or relapsed acute lymphocytic leukemia (R/R ALL) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and bl...
-
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-27 Nadia Gabarin, Michael Hack, Ryan Revilla, Donald M. Arnold, Ishac Nazy
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening prothrombotic disorder first identified following the introduction of adenoviral vector vaccines for COVID-19. The co...
-
Ankle arthrodesis and total ankle replacement in patients with congenital bleeding disorders suffering from severe ankle arthropathy Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-27 E. Carlos Rodriguez-Merchan
In patients with congenital bleeding disorders suffering from severe ankle arthropathy, when conservative treatment and joint-preserving surgical techniques fail, there are two possible non-joint-p...
-
Cross-cultural assessment of the influence of the COVID-19 pandemic on the perceived mental health and medical experiences of persons with inherited bleeding disorders and their parents/guardians Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Sylvia von Mackensen, Maria E. Santaella, Cynthia D. Nichols, Kate Khair, Angela Y. Lambing, Michelle L. Witkop
Objectives were to 1) assess COVID-19-associated medical and psychological challenges facing persons with inherited bleeding disorders (PIBD) and their parents/guardians (PG) in Germany, the US, an...
-
National strategic advocacy to manage patients with inherited bleeding disorders in low and lower-middle income countries Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Ampaiwan Chuansumrit, Theera Ruchutrakul, Nongnuch Sirachainan, Pimpun Kitpoka, Monratta Panuwannakorn, Panyu Panburana, Monthon Suwannuraks, Nantana Sri-Udomporn, Chusak Kijkunasathian, Suphaneewan Jaovisidha, Chirawat Utamakul, Rungrote Natesirinilkul, Bunchoo Pongtanakul, Chanchai Traivaree, Patcharee Komvilaisak, Ekawat Suwantaroj, Darintr Sosothikul, Pantep Angchaisuksiri, Ponlapat Rojnuckarin
Inherited bleeding disorders (IBDs) including hemophilia, von Willebrand disease, platelet disorders, mucocutaneous bleeding disorders and coagulation factor deficiencies are rarely found and under...
-
Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Roberto Lúcio Muniz, Ricardo Mesquita Camelo, Maiara Silva Araújo, Mariana Michel Barbosa, Augusto Afonso Guerra, Francisco de Assis Acurcio, Juliana Alvares-Teodoro
Emicizumab is a monoclonal antibody approved for prophylaxis against bleeds for people with hemophilia A (PwHA). A systematic review was conducted evaluating the efficacy/effectiveness and the safe...
-
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Marianna Criscuolo, Nicola Fracchiolla, Francesca Farina, Luisa Verga, Livio Pagano, Alessandro Busca
The recent introduction of targeted therapies, including monoclonal antibodies, tyrosine-kinase inhibitors, and immunotherapies has improved the cure rate of hematologic patients. The implication o...
-
Diagnosis of erythroid dysplasia by flow cytometry: a review Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Marc Sorigue
The diagnosis of myelodysplastic syndrome (MDS) is complex. Flow cytometric analysis of the myelomonocytic compartment can be helpful, but it is highly subjective and reproducibility by non-special...
-
Fatigue and health-related quality of life in patients with immune thrombocytopenia: a longitudinal assessment in China Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Wenhui Zhang, Shitong Xie, Rongfeng Fu, Yunfei Chen, Wei Liu, Ting Sun, Mankai Ju, Huiyuan Li, Feng Xue, Lei Zhang, Xiaofan Liu, Renchi Yang
There is lacking studies of longitudinally assessment of fatigue and health-related quality of life (HRQoL) among Chinese immune thrombocytopenia (ITP) adults. We aimed to evaluate changes in fatig...
-
Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 James A. Davis, Katelynn Granger, Alex Sakowski, Sara Goodwin, Amanda Herbst, Deidra Smith, Lindsey Hendrickson, Victoria R. Nachar
Published in Expert Review of Hematology (Vol. 16, No. 12, 2023)
-
The promise of novel treatments for severe chronic neutropenia Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 David C. Dale, Audrey Anna Bolyard, Vahagn Makaryan
Severe chronic neutropenia, i.e. absolute neutrophil count (ANC) less than 0.5 × 109/L, is a serious health problem because it predisposes patients to recurrent bacterial infections. Management rad...
-
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Si-Qi Li, Man Chen, Xi-Yi Huang, Hui Wang, Ying-Jun Chang
Minimal residual disease (MRD) has been an important biomarker for relapse prediction and treatment choice in patients with acute myeloid leukemia (AML). False-positive or false-negative MRD result...
-
In the era of primary prophylaxis in hemophilia, what types of orthopedic surgical interventions have been published in the 2020–2023 period and in which countries? Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 E. Carlos Rodriguez-Merchan
Primary prophylaxis has significantly reduced the number of orthopedic surgical procedures performed on patients with hemophilia (PWH) worldwide. However, studies on orthopedic surgery in PWH are s...
-
Use of direct oral anticoagulants and low molecular weight heparin in venous thromboembolism associated with cancer: real-world evidence in Argentina Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 MM. Clavijo, JI. Ruiz, C. Muñoz, A. Vicente Reparaz M de Los, MA. Acuña, CE. Casali, MF. Aizpurua, CV. Mahuad, ME. Zerga, A. Ventura, GM. Garate
Venous thromboembolism (VTE) and major bleeding (MB) are common in cancer patients. Reduced-doses of antithrombotics as secondary prophylaxis have limited data. This work aims to describe and to co...
-
Total elbow arthroplasty in hemophilia: a high-risk surgical procedure Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 E. Carlos Rodriguez-Merchan
Published in Expert Review of Hematology (Vol. 16, No. 12, 2023)
-
The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Katie Maurer, Robert J. Soiffer
The curative basis of allogeneic hematopoietic stem cell transplantation (HSCT) relies in part upon the graft versus leukemia (GvL) effect, whereby donor immune cells recognize and eliminate recipi...
-
The role of staging in multiple myeloma Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Leonid L. Yavorkovsky
The importance of cancer staging is determined by how accurately it can predict prognosis, and how useful it is for treatment decisions. Compared to other malignancies, multiple myeloma (MM) stagin...
-
Sequencing novel agents in the treatment of classical Hodgkin lymphoma Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Burhan Ferhanoglu, Murat Ozbalak
Classical Hodgkin lymphoma (cHL) is a curable disease, with durable remission achieved in about 80% of patients following first-line treatment. Three new drugs were introduced to the daily use in c...
-
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Giancarlo Castaman, Michiel Coppens, Steven W Pipe
Etranacogene dezaparvovec is the first gene therapy approved for treatment of adults with severe and moderately severe hemophilia B.This review describes the results of the clinical trial program o...
-
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Xiao Chen Ma, Xiao Lv, Ying Li
After therapy, approximately 15% of individuals with Hodgkin’s lymphoma (HL) develop relapsed or drug-resistant Hodgkin’s lymphoma (r/rHL). r/rHL has a high fatality rate and poor therapeutic progn...
-
Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Xin He, Shan-Na Wei, Wen-Wen Qin, Nan Geng, Bin Li, Shan Song, Ping Wang
Currently, immune checkpoint inhibitors (ICIs) therapy is one of the main methods of treatment in non-small cell lung cancer (NSCLC). This study aimed to explore the risk factors of VTE and evaluat...
-
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials? Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-18 Manuel R. Espinoza-Gutarra, Sikander Ailawadhi
Published in Expert Review of Hematology (Vol. 16, No. 12, 2023)
-
Predicting the development of hemophilic arthropathy in patients with hemophilia based on patient age: a retrospective single-center database study Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-12-04 Radovan Kubeš, Martin Stollin, Štěpán Magersky, Maryan Bobelyak, Jan Vaculík, Josef Včelák, Aleš Antonín Kuběna, Jan Loužil, Peter Salaj
Patients with hemophilia (PWH) develop hemophilic arthropathy of the major joints due to recurrent hemarthrosis. This study retrospectively estimated the age at which PWH may expect to develop hemo...
-
Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-28 Andrea Boccatonda, Elena Campello, Chiara Simion, Paolo Simioni
both symptomatic and asymptomatic SARS-CoV-2 infections – coined Coronavirus disease 2019 (COVID-19) – have been linked to a higher risk of cardiovascular events after recovery.our review aims to s...
-
Challenges in the diagnosis of thrombotic thrombocytopenic purpura Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Rance C. Siniard, Radhika Gangaraju, Jori E. May, Marisa B. Marques
Immune-mediated TTP (iTTP) is a rare condition without pathognomonic signs and symptoms. For this reason, the diagnosis of iTTP may be delayed or even missed, with potentially catastrophic conseque...
-
The role of intraarticular injections of hyaluronic acid in joint pain relief in hemophilic arthropathy Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 E. Carlos Rodriguez-Merchan
Chronic pain in hemophilic patients is due to joint degeneration associated with hemophilic arthropathy. In addition to appropriate hematological treatment (primary prophylaxis), pharmacologic mana...
-
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Ramón García-Sanz, Zachary R. Hunter, Stéphanie Poulain, Marzia Varettoni, Roger G. Owen
Waldenström’s macroglobulinemia (WM) is defined as a lymphoplasmacytic lymphoma (LPL) with immunoglobulin M (IgM) monoclonal gammopathy and morphologic evidence of bone marrow infiltration by LPL. ...
-
Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Stefano Molica
Published in Expert Review of Hematology (Vol. 16, No. 11, 2023)
-
Looking to the future of gene therapy for hemophilia A and B Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Radoslaw Kaczmarek, Roland W. Herzog
Published in Expert Review of Hematology (Vol. 16, No. 11, 2023)
-
Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand? Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 David R. Spillane, Sarit Assouline
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are generally characterized by a poor prognosis with currently available therapies. Immunotherapies have already seen success in trea...
-
Quality of life considerations and management in patients with myelodysplastic syndrome Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Zhaoyun Liu, Xintong Xu, Kai Ding, Rong Fu
This study aimed to identify the factors affecting the quality of life (QOL) and functional status of patients with MDS.We reviewed the literature published in PUBMED over the past 30 years and sea...
-
Targeting von Willebrand disease: the current status and future directions of management therapies Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Massimo Franchini, Daniele Focosi
von Willebrand disease (VWD) is the commonest inherited bleeding disorder, and is typically caused by deficits in the quantity or quality of von Willebrand factor (VWF).This review describes the ma...
-
Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-11-17 Zaina Inam, John F. Tisdale, Alexis Leonard
Hematopoietic stem cell transplant (HSCT) is the only readily available curative option for sickle cell disease (SCD). Cure rates following human leukocyte antigen (HLA)-matched related donor HSCT ...
-
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-09-08 Akihiro Ohmoto, Shigeo Fuji
Cytarabine and anthracycline combination therapy (7 + 3 regimen) is the standard care for induction chemotherapy in adult patients with acute myeloid leukemia (AML). Although this intensive regimen...
-
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-09-08 Simon Cheah, Julie K. Bassett, Fiona J. Bruinsma, John Hopper, Harindra Jayasekara, Doug Joshua, Robert J. MacInnis, H. Miles Prince, Melissa C. Southey, Claire M. Vajdic, Marina T. van Leeuwen, Nicole Wong Doo, Simon J. Harrison, Dallas R. English, Graham G. Giles, Roger L. Milne
While remaining incurable, median overall survival for MM now exceeds 5 years. Yet few studies have investigated how modifiable lifestyle factors influence survival. We investigate whether adiposit...
-
Immune thrombocytopenia: a review on the pathogenetic role of immune cells Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-09-08 Forogh Nokhostin, Fatemeh Bakhshpour, Seyed Mohammad Sadegh Pezeshki, Reyhane Khademi, Najmaldin Saki
Immune thrombocytopenia [ITP] is a common bleeding disorder with an isolated platelet count of less than 100 × 109/L.Relevant literature from 2003 to 2022 was retrieved and reviewed from the Google...
-
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-09-07 Robert F. Sidonio Jr, Alexis A. Thompson, Flora Peyvandi, Oleksandra Stasyshyn, Seoh Leng Yeoh, Darintr Sosothikul, Ali Bulent Antmen, Caterina Maggiore, Werner Engl, Bruce Ewenstein, Srilatha Tangada
To determine the immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients (PUPs) with severe hemophilia A (HA).This prospective, phase 3 study (NCT02615691) w...
-
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-08-21 Steven W. Pipe, Amy L. Dunn, Guy Young
Bypassing agents (BPAs) are used to treat acute bleeding episodes, manage bleeding during perioperative care, and prophylactically minimize bleed occurrence in persons with hemophilia A or B with i...
-
Role of daratumumab in the frontline management of multiple myeloma: a narrative review Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-08-18 Sanjeev Yadav, Sadashivudu Gundeti, Abhay Bhave, Uttiya Deb, Jitendra Dixit, Kundan Mishra
The prevalence of multiple myeloma (MM) has gradually increased over the last few decades in India due to growing population, better disease awareness, and improved diagnostic procedures. Despite s...
-
Patient-centered care in von Willebrand disease: are we there yet? Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-08-15 Grace H Tang, Jecko Thachil, Mackenzie Bowman, Carine Bekdache, Paula D James, Michelle Sholzberg
ABSTRACT Introduction Von Willebrand Disease is the most common inherited bleeding disorder. Paradoxically, affected individuals are often misdiagnosed and experience substantial diagnostic delay. There are sex-specific health disparities in VWD rooted in the stigmatization of vaginal bleeding, which leads to symptom dismissal, lack of timely access to care and lower health-related quality of life
-
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-08-10 Helen Philippou, Evi X. Stavrou
Published in Expert Review of Hematology (Vol. 16, No. 10, 2023)
-
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-08-01 Yousef Alabrach, Amir A. Mahmoud, Ali Abdelhay, Mohamad Mansour, Saryia Adra
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults, and its incidence is higher in elderly individuals. This study aims to examine the burden of CLL in the United States (U...
-
Genetic basis of ß-thalassemia in families of pashtun ethnicity in Dera Ismail Khan district of Khyber Pakhtun-Khwa province, Pakistan Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-08-01 Muhammad Ayaz, Muhammad Muzammal, Sami Siraj, Sumaya Fatima, Sana Fatima, Jabbar Khan, Muzammil Ahmad Khan, Muhammad Ishaq Shah, Zia Ur Rehman, Lin Wei
ABSTRACT Objectives The objective of current genetic research was to verify the genetic basis of ß-thalassemia and its pattern of inheritance in families of Pashtun ethnicity in District Dera Ismail Khan, Pakistan. Methodology Blood samples from clinically diagnosed five unrelated ß-thalassemia families were collected and target Sanger Sequencing of HBB gene was done. Moreover, in silico analysis including
-
Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-27 Peter Valent, Irina Sadovnik, Barbara Peter, Daniel Ivanov, Axel Schulenburg, Emir Hadzijusufovic, Michael Willmann, Thomas Rülicke, Harald Herrmann, Werner Rabitsch, Heidrun Karlic, Karoline V. Gleixner, Wolfgang R. Sperr, Gregor Hoermann, Maik Dahlhoff, Michael Pfeilstöcker, Felix Keil, Thomas Lion, Thomas W. Grunt
ABSTRACT Introduction The Vienna Cancer Stem Cell Club (VCSCC) was launched by a group of scientists in Vienna in 2002. Areas covered Major aims of the VCSCC are to support research on cancer stem cells (CSC) in hematopoietic malignancies and to translate CSC-related markers and targets into clinical application. A primary focus of research in the VCSCC is the leukemic stem cell (LSC). Between 2013
-
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-27 Françoise Huguet, Delphine Réa, Emilie Cayssials, Gabriel Etienne, Franck-Emmanuel Nicolini
ABSTRACT Introduction Ponatinib exhibits a high inhibition potency on wild-type and most mutated forms of the BCR:ABL1 kinase, but also a significant cardiovascular toxicity. Improving the efficacy/safety ratio should allow patients to safely draw benefit from the drug. Areas covered Based on pharmacological findings and international guidelines on chronic myeloid leukemia and cardiovascular risk management
-
Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-23 Kieran D. Sahasrabudhe, Mary Albrethsen, Alice S. Mims
ABSTRACT Introduction Acute myeloid leukemia (AML) is an aggressive disease which has traditionally been treated with intensive chemotherapy. Survival in patients with high-risk cytogenetic and molecular subsets has been poor with this approach due to suboptimal responses seen with intensive chemotherapy and due to many patients with higher risk disease being older and unable to tolerate intensive
-
Role of volumetric analyses on [18F]FDG PET/CT in pediatric Hodgkin lymphoma Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-18 Egesta Lopci, Maurizio Mascarin
Published in Expert Review of Hematology (Vol. 16, No. 9, 2023)
-
Impact of genotype on clinical course in sickle cell disease and the utility of neutrophil-lymphocyte ratio: a ten-year single-institution experience Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-04 Akash Mathavan, Akshay Mathavan, Mohit Mathavan, Urszula Krekora, Aaron J Winer, Ellery Altshuler, Russell Wnek, Keegan Hones, Arushi Thaper, Richard Artola, Logan Pucci, Patrick Haley, Del Carter, William Snead, Denise Manfrini, Daniel F. Leach III, Jess D DeLaune, Molly W Mandernach
ABSTRACT Background Sickle cell disease (SCD) is a diverse group of blood disorders with significant global disease burden. Contemporary interest in the underlying inflammatory paradigm of SCD has emphasized the role of the neutrophil–lymphocyte ratio (NLR) as a prognostic inflammatory marker. Methods We retrospectively reviewed 268 hospitalized patients with SCDs of different genotypes (HbSS, HbSβ0
-
Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-04 E. Carlos Rodriguez-Merchan
ABSTRACT Introduction It is important to know the current status of hemophilic arthropathy diagnoses, treatments, complications, and outcomes in developed countries. Areas covered A bibliographic search in PubMed for articles published from 1 January 2019 through 12 June 2023 was performed. Expert opinion In developed countries with specialized hemophilia treatment centers, primary hematological prophylaxis
-
Effect of hydroxyurea on erythrocyte apoptosis in hemoglobinopathy patients Expert Rev. Hematol. (IF 2.8) Pub Date : 2023-07-03 Neha Kargutkar, Anita Nadkarni
ABSTRACT Background Hydroxyurea (HU) therapy improves the clinical severity of patients with hemoglobinopathies. Few studies have documented some mechanisms of HU, but the exact mechanism of action is unknown. Phosphatidylserine on erythrocytes is responsible for apoptosis. In this study, we investigate the expression of phosphatidylserine on the erythrocytes surface of hemoglobinopathies before and